Literature DB >> 15482267

Towards evidence-based use of serum tumour marker requests: an audit of use in a tertiary hospital.

S Loi1, A M M Haydon, J Shapiro, M A Schwarz, H G Schneider.   

Abstract

BACKGROUND: Serum tumour markers (TM) are often measured in hospital patients. The reasons for their use and their benefits with regards to earlier cancer diagnosis and patient management are not known. AIMS: To identify the patterns of TM use in a tertiary hospital and to determine the usefulness and appropriateness of requests in this setting.
METHODS: A cross-sectional, retrospective study of TM ordered over a 3-month period was conducted. Data were obtained from patient records. CA-125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), and alpha-fetoprotein (AFP) were studied. Prostate specific antigen was not separately investigated. The reasons for ordering, usefulness and appropriateness of use were defined prior to analysis.
RESULTS: A total of 476 TM was ordered in 373 patients. One hundred and six (22%) of all results were abnormal by laboratory criteria. AFP was the most popular test ordered. Forty-seven per cent of patients had no cancer diagnosis. Oncological units (ONC) ordered 27% of tests. The most popular reasons for TM ordering were for screening (36%) followed by diagnostic aid (19%). ONC units ordered TM mainly for monitoring disease status, as opposed to non-ONC units who ordered TM usually for diagnostic aid. TM were deemed appropriately ordered in 69% of cases. Twenty-nine per cent of TM were helpful in patient management. Only four results (<1%) aided in diagnosis.
CONCLUSIONS: The reasons and appropriateness of TM use varied depending on the specialization of the requesting clinician. The current serum TM are most useful as aids in cancer patients, rather than for diagnosis (P <0.0001). Apart from AFP, these TM seem to have limited use in the general medical, non-oncological patients. Guidelines for their use in this setting are needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482267     DOI: 10.1111/j.1445-5994.2004.00671.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  4 in total

1.  Markedly elevated CA19-9 associated with benign ovarian cyst and ascites.

Authors:  Oliver Brain; Laura H W Brown; Shaila Suvarna; Roger Chapman
Journal:  BMJ Case Rep       Date:  2009-03-20

2.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements.

Authors:  Catharine M Sturgeon; Barry R Hoffman; Daniel W Chan; Soo-Ling Ch'ng; Elizabeth Hammond; Daniel F Hayes; Lance A Liotta; Emmanuel F Petricoin; Manfred Schmitt; O John Semmes; Györg Söletormos; Elena van der Merwe; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2008-07-07       Impact factor: 8.327

Review 3.  The landscape of inappropriate laboratory testing: a 15-year meta-analysis.

Authors:  Ming Zhi; Eric L Ding; Jesse Theisen-Toupal; Julia Whelan; Ramy Arnaout
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

4.  Injudicious use of laboratory facilities in tertiary care hospitals at Rawalpindi, Pakistan: a cross-sectional descriptive study.

Authors:  Muhammad Farooq Malik; Dilshad Ahmed Khan; Wafa Munir Ansari; Farooq Ahmad Khan
Journal:  BMC Health Serv Res       Date:  2013-11-26       Impact factor: 2.655

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.